Cytokinetics Inc’s recent filing unveils that its Director PARSHALL B LYNNE unloaded Company’s shares for reported $0.32 million on Nov 19 ’25. In the deal valued at $64.73 per share,5,000 shares were sold. As a result of this transaction, PARSHALL B LYNNE now holds 22,933 shares worth roughly $1.55 million.
Then, B LYNNE PARSHALL bought 5,000 shares, generating $330,800 in total proceeds.
Before that, Malik Fady Ibraham sold 2,200 shares. Cytokinetics Inc shares valued at $146,190 were divested by the EVP Research & Development at a price of $66.45 per share. As a result of the transaction, Malik Fady Ibraham now holds 140,610 shares, worth roughly $9.5 million.
A number of analysts have revised their coverage, including Barclays’s analysts, who began to cover the stock in late April with a ‘”an Overweight”‘ rating. Citigroup began covering CYTK with “Buy” recommendation on February 07, 2025. Stifel started covering the stock on January 22, 2025. It rated CYTK as “a Buy”.
Price Performance Review of CYTK
On Tuesday, Cytokinetics Inc [NASDAQ:CYTK] saw its stock jump 0.51% to $67.55. Over the last five days, the stock has gained 2.10%. Cytokinetics Inc shares have risen nearly 41.70% since the year began. Nevertheless, the stocks have risen 43.60% over the past one year. While a 52-week high of $67.98 was reached on 11/17/25, a 52-week low of $29.31 was recorded on 05/15/25.
Levels Of Support And Resistance For CYTK Stock
The 24-hour chart illustrates a support level at 66.46, which if violated will result in even more drops to 65.37. On the upside, there is a resistance level at 68.18. A further resistance level may holdings at 68.81.
How much short interest is there in Cytokinetics Inc?
A steep rise in short interest was recorded in Cytokinetics Inc stocks on 2025-11-14, growing by 0.18 million shares to a total of 14.38 million shares. Yahoo Finance data shows the prior-month short interest on 2025-10-15 was 14.2 million shares. There was a rise of 1.29%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on November 08, 2024 when RBC Capital Mkts began covering the stock and recommended ‘”an Outperform”‘ rating along with a $80 price target.
